Acute Pain - Pipeline Review, H1 2012

Global Markets Direct, February 2012, Pages: 113

Acute Pain – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Acute Pain - Pipeline Review, H1 2012', provides an overview of the Acute Pain therapeutic pipeline. This report provides information on the therapeutic development for Acute Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Pain. 'Acute Pain - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acute Pain.
- A review of the Acute Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acute Pain pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Acute Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acute Pain pipeline depth and focus of Acute Pain therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Acute Pain Therapeutic Products under Development, Key Players in Acute Pain Therapeutics, Acute Pain Pipeline Overview, Acute Pain Pipeline, Acute Pain Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acute Pain Overview
Therapeutics Development
An Overview of Pipeline Products for Acute Pain
Acute Pain Therapeutics under Development by Companies
Acute Pain Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Acute Pain Therapeutics – Products under Development by Companies
Acute Pain Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Acute Pain Therapeutics Development
Merck & Co., Inc.
Pacira Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc.
Sun Pharmaceutical Industries Limited
Anavex Life Sciences Corp.
NeurogesX, Inc.
Nuvo Research Inc.
CombinatoRx, Incorporated
Applied Pharma Research USA
Intas Pharmaceuticals Ltd.
Advinus Therapeutics Pvt. Ltd.
Transdel Pharmaceuticals, Inc.
BIOALVO S.A.
QRxPharma Limited
Xenome Ltd.
Iroko Pharmaceuticals, LLC
Xanodyne Pharmaceuticals, Inc.
KemPharm, Inc.
Troikaa Pharmaceuticals Ltd.
RaQualia Pharma Inc.
Mt Cook Pharma. Inc.
Cytogel Pharma, LLC
Acute Pain – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Ketotransdel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Arcoxia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BLV0704 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nucynta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NGX-1576 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NGX-9674 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NGX-5752 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NGX-6052 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANAVEX 1007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KP201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XP21B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MoxDuo IR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Eptifibatide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MCP-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xen2174 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T-Type Calcium Channels Blockers - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANAVEX 1519 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ketamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sufentanil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Remifentanil + Clonidine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RQ-00000007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RQ-00000008 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diclofenac Sodium Matrix Patch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Topical Diclofenac Solution - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IN-PHARM-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
D-9998 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NCE 1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NCE 2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IP 940 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IP 880 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Z212 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DepoNSAID - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARX-04 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANAVEX 1066 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NRI-ANA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MRX-7EAT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
THA903 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyt-1010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RQ-00317076 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Target 1 For Pain - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acute Pain Therapeutics – Drug Profile Updates
Acute Pain Therapeutics – Discontinued Products
Acute Pain Therapeutics - Dormant Products
Acute Pain – Product Development Milestones
Featured News & Press Releases
Jan 19, 2012: Merck Resolves Vioxx Litigation In Canada
Nov 30, 2011: Cara Therapeutics Starts Phase I Clinical Trial Of New Oral Peripherally-Acting Kappa Opioid Agonist
Nov 14, 2011: Nektar Therapeutics Presents Positive Preclinical Data On NKTR-192 At 41st Annual Meeting Of Society For Neuroscience
Nov 08, 2011: QRxPharma Receives Target Date For FDA Action On MoxDuo IR NDA
Oct 17, 2011: Acura Pharmaceuticals Provides Update On Opioid Product Licensed To Pfizer
Sep 06, 2011: IPMC-CNRS Spin-Off Theralpha Receives Major Grant For Pain Drug Development
Aug 31, 2011: Cipher Receives Health Canada Approval For Extended-Release Tramadol
Aug 11, 2011: Lannett Launches Morphine Sulfate Oral Solution
Jul 01, 2011: Acura Pharmaceuticals Receives $20m Milestone Payment From Pfizer For OXECTA
Jun 23, 2011: FDA Accepts Endo Pharmaceuticals's Complete Response For New Formulation Of OPANA ER
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Acute Pain, H1 2012
Products under Development for Acute Pain – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Merck & Co., Inc., H1 2012
Pacira Pharmaceuticals, Inc., H1 2012
AcelRx Pharmaceuticals, Inc., H1 2012
Sun Pharmaceutical Industries Limited, H1 2012
Anavex Life Sciences Corp., H1 2012
NeurogesX, Inc., H1 2012
Nuvo Research Inc., H1 2012
CombinatoRx, Incorporated, H1 2012
Applied Pharma Research USA, H1 2012
Intas Pharmaceuticals Ltd., H1 2012
Advinus Therapeutics Pvt. Ltd., H1 2012
Transdel Pharmaceuticals, Inc., H1 2012
BIOALVO S.A., H1 2012
QRxPharma Limited, H1 2012
Xenome Ltd., H1 2012
Iroko Pharmaceuticals, LLC, H1 2012
Xanodyne Pharmaceuticals, Inc., H1 2012
KemPharm, Inc., H1 2012
Troikaa Pharmaceuticals Ltd., H1 2012
RaQualia Pharma Inc., H1 2012
Mt Cook Pharma. Inc., H1 2012
Cytogel Pharma, LLC, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Acute Pain Therapeutics – Drug Profile Updates
Acute Pain Therapeutics – Discontinued Products
Acute Pain Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Acute Pain, H1 2012
Products under Development for Acute Pain – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2013
• Acute Pain - Pipeline Review, H2 2012
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Acute Respiratory Distress Syndrome - Pipeline Review, H1 2013
• Candidiasis - Pipeline Review, H1 2013
• Postherpetic Neuralgia - Pipeline Review, H1 2013
• Burns - Pipeline Review, H1 2013
• Pain Therapeutics - Drugs, Markets and Companies
• Drug Addiction – Pipeline Review, H1 2013
• Herpes Simplex Infections - Pipeline Review, H1 2013